Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease?

OncoImmunology

Volumn 1, Issue 4, 2012, Pages 560-562

  Cioffi, Michele ^a   Heeschen, Christopher ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

Author keywords

Bispecific antibody; Cancer stem cells; CD133; EpCAM; Pancreatic cancer; Xenograft

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC ANTIBODY MT110; CD133 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; EPITHELIAL CELL ADHESION MOLECULE; GEMCITABINE; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE ANTIGEN RECEPTOR; STAGE SPECIFIC EMBRYO ANTIGEN 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DOSE TIME EFFECT RELATION; DRUG DOSE ESCALATION; EMBRYONIC STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; NONHUMAN; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

EID: 84877981531     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19368     Document Type: Article

References (10)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300; PMID: 20610543; http://dx.doi.org/10.3322/caac.20073
2. Matano E, Tagliaferri P, Libroia A, Damiano V, Fabbrocini A, De Lorenzo S, et al. Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. Br J Cancer 2000; 82: 1772-5; PMID:10839289; http://dx.doi.org/10.1054/bjoc.1999.1139
3. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367:645-8; PMID:7509044; http://dx.doi.org/10.1038/367645a0
4. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1:313-23; PMID:18371365; http://dx.doi.org/10.1016/j.stem. 2007.06.002
5. Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009; 137:1102-13; PMID:19501590; http://dx.doi.org/10. 1053/j.gastro.2009.05.053
6. Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, et al. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011; 9:433-46; PMID:22056140; http://dx. doi.org/10.1016/j.stem.2011.10.001
7. Visus C, Wang Y, Lozano-Leon A, Ferris RL, Silver S, Szczepanski MJ, et al. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8+ T cells. Clin Cancer Res 2011; 17:6174-84; PMID:21856769; http://dx.doi.org/10.1158/1078-0432.CCR-11-1111
8. Cioffi M, Dorado J, Baeuerle PA, Heeschen C. EpCAM/ CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells. Clin Cancer Res 2012; 18:465-74; PMID: 22096026; http://dx.doi.org/10.1158/1078-0432.CCR-11-1270
9. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009; 69:5627-9; PMID:19584271; http://dx.doi.org/ 10.1158/0008-5472.CAN-09-0654
10. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15; PMID:18485877; http://dx.doi.org/10. 1016/j.cell.2008.03.027